FORT LEE, N.J., Dec. 4 /PRNewswire-FirstCall/ -- Alpharma Inc. , a leading global specialty pharmaceutical company, announced today Stefan Aigner, MD, has joined the company as Executive Vice President, Corporate and Business Development. This newly created role will report to Dean Mitchell, President and CEO.
Dr. Aigner has more than twenty years of broad healthcare experience. Prior to joining Alpharma, Dr. Aigner was co-founder and Executive Vice President of Business Development for Reliant Pharmaceuticals, Inc., a specialty pharmaceutical company. During his seven year tenure with Reliant, Dr. Aigner led the company through multiple product acquisitions and in- licensing transactions and was responsible for building a unique cardiovascular portfolio through strong partnerships with leading U.S. and European companies. Prior to Reliant, Dr. Aigner was a consultant with The Wilkerson Group, a leading healthcare consulting firm, where he focused on development of corporate strategies, assessment of new products, and evaluation of potential partnering candidates.
He has also served in various medical and scientific roles within leading medical institutions, including the University of Erlangen, Germany; University of Birmingham, U.K.; Free University of Brussels, Belgium; and Mt. Sinai Hospital, New York.
"This new role will be crucial to Alpharma's ability to execute its growth strategy, and I am pleased to have an executive of Stefan's caliber and expertise leading our global business development efforts," said Dean Mitchell, President and Chief Executive Officer of Alpharma. "Stefan will be focused on leveraging the company's current market competencies with complementary business development alliances to accelerate the company's growth."
Dr. Aigner graduated summa cum laude with a degree in medicine from the University of Erlangen, Germany, and is a Chartered Financial Analyst (CFA).
Alpharma press releases are also available at our website: http://www.alpharma.com.
Alpharma Inc. is a global specialty pharmaceutical company with leadership positions in products for humans and animals. Alpharma is presently active in more than 60 countries. Alpharma has a growing branded franchise in the chronic pain market with its morphine-based extended release KADIAN(R) product. In addition, Alpharma is among the world's leading producers of several specialty pharmaceutical-grade bulk antibiotics and is internationally recognized as a leading provider of pharmaceutical products for poultry and livestock.
Alpharma Inc.CONTACT: Kathleen Makrakis, VP, Investor Relations, +1-202-228-5085,kathleen.makrakis@alpharma.com
Web site: http://www.alpharma.com/
